Actinic Keratosis: Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

Actinic Keratosis: Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

PR Newswire

LAS VEGAS, November 13, 2018

LAS VEGAS, November 13, 2018 /PRNewswire/ --

Actinic Keratosis The prevalent population of Actinic Keratosis in 7MM countries is expected to increase at a CAGR of 0.85% for the study period [2016-2027] 

Actinic keratosis (AK) is a chronic and prevalent disease affecting areas of sun-exposed skin where visible and subclinical, non-visible lesions coexist. AK lesions are being represented as small scaly patches that can be flat or slightly raised. Their colour can range from one's skin tone to a reddish-brown colour. AK is more prevalent among male than female population.

     (Logo: https://mma.prnewswire.com/media/776895/DelveInsight_Logo.jpg )

According to DelveInsight analysis, prevalent population of Actinic Keratosis in 7MM countries is expected to increase at a CAGR of 0.85% for the study period [2016-2027]. DelveInsight's analysts estimate the United States has the highest prevalence of Actinic Keratosis with 66,144,416 prevalent population in 2016. Among the EU5 countries, Germany has the highest prevalent population with 8,230,614 cases followed by United Kingdom which has prevalent population of 5,398,511 in 2016. On the other hand, Japan has the lowest prevalent population with 683,858 cases in 2016.

Click here to get a free sample report: https://www.delveinsight.com/dev-sample.php?form_name=Actinic-Keratosis--Market-Insight,-Epidemiology-and-Market-Forecast---2027

Going further to market outlook the therapeutic landscape of Actinic Keratosis is segmented widely into three main therapies that include the lesion directed Destructive Therapies (cryosurgery, curettage, laser, dermabrasion, surgery etc.), field directed Topical Therapies (imiquimod, ingenol mebutate, 5-fluorouracil, and others) and Photodynamic therapies (such as Levulan Kerastick, Metvixia cream). Among the three class therapies, Destructive Therapy is the most prescribed, that leads to the highest market size, followed by topical therapies.

The market size of Actinic Keratosis in the seven major markets was estimated to be USD 4659.58 million in 2016. The United States account for the largest market share of Actinic Keratosis in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. 

Among the currently approved topical therapies i.e., Imiquimod 3.75% (Zyclara), Imiquimod 5% (Aldara), 5-fluorouracil (Efudex; Carac), Diclofenac 3% (Solaraze), Ingenol mebutate (Picato) and others, Imiquimod 3.75% and 5% was observed to account for maximum market share followed by 5-fluorouracil in the United States. Expected launch of upcoming topical therapies such as KX-01 (Athenex), VDA-1102 (Vidac Pharma), DFD-07 (Promius Pharma) and SOR 007 (DFB Soria) will propel the market forward during the forecast period [2018-2027]. Out of the above-mentioned therapies, DelveInsight expects that KX-01 (Athenex (Kinex Pharmaceuticals)), which is a small molecule that acts as a dual Src/pre-tubulin inhibitor, shall dominate the market size of AK in coming years.

The report provides an overview of the disease and market size of Actinic Keratosis for the seven major markets i.e., the United States, EU5 (France, Germany, Italy, Spain, the UK) and Japan. This Report covers the overview, various treatment practices, and Actinic Keratosis forecasted epidemiology from 2018 to 2027, segmented by seven major markets.

Request a free Webex Demo of report: https://www.delveinsight.com/report-store/actinic-keratosismarket-insight-epidemiology-and-market-forecast

Reasons to buy this report: 

Companies Covered: 

  1. Athenex
  2. Vidac Pharma
  3. DFB Soria
  4. Promius Pharma
  5. Mylan
  6. LEO Pharma

And many others

Drugs covered: 

  1. KX-01
  2. VDA-1102
  3. DFD-07
  4. SOR 007

And many others

Key Topics Covered:   

1. Key Insights

2. Actinic Keratosis: Market Overview at a Glance

3. Disease Background and Overview  

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. 7MM Total Prevalent Patient Population of Actinic Keratosis

5. Country Wise-Epidemiology of Actinic Keratosis Disease

5.1. United States; EU5 Countries; Japan

6. Treatment Practices

6.1. Treatment goals

6.2. Lesion-Directed Therapies: First line treatment

6.3. Field-Directed Therapies: Topical therapies

6.4. Photodynamic therapy

6.5. British Association of Dermatologists Guidelines for the care of patients with actinic keratosis

2017

6.6. Evidence and consensus based (S3) Guidelines for the Treatment of Actinic Keratosis

7. Current Unmet Needs

8. Marketed Drugs

8.1. Aldara: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals)

8.1.1. Drug Description

8.1.2. Mechanism of Action

8.1.3. Regulatory Milestones

8.1.4. Advantages & Disadvantages

8.1.5. Safety and Efficacy of Aldara

8.1.6. Product Profile

8.2. Zyclara: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals)

8.3. Solaraze: Sandoz Pharmaceuticals

8.4. Efudex: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals)

8.5. Carac: Bausch Health Companies (Formerly known as Valeant Pharmaceuticals)

8.6. Picato: LEO Pharma

8.7. Actikerell: Almirall S.A.

8.8. Fluoroplex: Aqua Pharmaceuticals

8.9. Ameluz: Biofrontera

8.10. Metvixia: Galderma

8.11. Levulan Kerastick: DUSA Pharmaceuticals

8.12. Alacare: Photonamic GmbH & Co. KG

8.13. Eryfotona AK-NMSC SPF 100+ Fluid: ISDIN Corp

9. Key Cross Competition

10. Emerging Drugs

11. Actinic Keratosis: 7 Major Market Analysis

11.1. Key Findings

11.2. Total Market Size of Actinic Keratosis in 7MM

11.3. Market Size of Actinic Keratosis by therapies, in 7MM

11.4. Market Size of Topical Therapies for Actinic Keratosis, in 7MM

12. The United States Market Outlook of Actinic Keratosis

13. EU-5 Countries: Market Outlook

14. Germany Market outlook of Actinic Keratosis

15. France Market outlook of Actinic Keratosis

16. Italy Market outlook of Actinic Keratosis

17. Spain Market outlook of Actinic Keratosis

18. United Kingdom Market outlook of Actinic Keratosis

19. Japan Market outlook of Actinic Keratosis

20. Market Drivers

21. Market Barriers

22. Appendix

22.1. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+91-9650213330

Voltar noticias em Inglês